【加科思-B(01167.HK):KRAS抑制剂戈来雷塞注册性临床数据在医学期刊《自然医学》发布】加科思-B(01167.HK)发布公告,公司自主研发的KRAS抑制剂戈来雷塞注册性临床试验数据在医学期刊《自然医学》(Nature Medicine)发布。在文章中,加科思首次完整公开戈来雷塞治疗KRAS G12C突变的二线或以上肺癌患者的完整数据。

金融界
07 Jan
加科思-B(01167.HK)发布公告,公司自主研发的KRAS抑制剂戈来雷塞注册性临床试验数据在医学期刊《自然医学》(Nature Medicine)发布。在文章中,加科思首次完整公开戈来雷塞治疗KRAS G12C突变的二线或以上肺癌患者的完整数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10